
An Update from LoQus23
LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic
If you want to help the Huntington’s Disease community, we are looking for people willing to join forces and create something together
If you want to start your own association to support HD, we can help you understand how
Your donation will help us supporting individuals and families that are affected by HD

LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic

New Phase 1 POINT-HD study starts for selective huntingtin-lowering approach Dear Huntington’s community leaders, Following your request to receive updates about our research efforts, we are pleased to

One of the hardest parts of living with Huntington’s disease isn’t the symptoms themselves, it’s navigating the medical system. From rushed appointments to misunderstanding symptoms, to being doubted